Daiichi Sankyo Company, Limited (DSNKY) Stock

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes. Other notable products in this area are prasugrel, an antiplatelet agent; edoxaban, an anticoagulant; olmesartan, an antihypertensive; and pravastatin for hypercholesterolemia. Neurology and Pain Management: Offerings include mirogabalin for pain relief, lacosamide as an anti-epileptic agent, memantine for Alzheimer's disease, and loxoprofen, an anti-inflammatory analgesic. Bone Health: Denosumab is available for conditions like osteoporosis and other bone disorders. Gastrointestinal and Other Specialized Treatments: This category features esomeprazole for ulcer treatment, silodosin for dysuria, and ferric carboxymaltose and iron sucrose injections to address anemia. Infectious Diseases and Immunology: Daiichi Sankyo markets laninamivir for anti-influenza treatment, levofloxacin as an antibacterial agent, and a range of vaccines including adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. Beyond prescription medications, the company also supplies a variety of consumer healthcare products: Over-the-Counter Remedies: Lulu, a combination cold remedy, and Loxonin S, an antipyretic/anti-inflammatory analgesic. Dermatology and Personal Care: Transino, aimed at improving melasma and treating spots/freckles; Minon skincare products; and oral care solutions like Breath Labo and Clean Dental. Furthermore, Daiichi Sankyo's operations extend to pharmaceuticals and drugs for animals, cosmetics, medical equipment, various food products, drinking water, and active pharmaceutical ingredients (APIs) and intermediates. The company is also engaged in strategic collaborations, notably with Guardant Health to develop Guardant360 CDx, a companion diagnostic specifically for Enhertu in patients with advanced metastatic non-small cell lung cancer. Established in 1899, Daiichi Sankyo Company, Limited maintains its corporate headquarters in Tokyo, Japan.

Daiichi Sankyo Company, Limited is headquartered in JP.

Daiichi Sankyo Company, Limited (DSNKY) stock trades at $17.71 with a market capitalization of $32.24B. The stock is valued at a price-to-earnings (P/E) ratio of 21.23, price-to-book of 3.00, price-to-sales of 2.30. Over the past 52 weeks the stock has ranged between $14.98 and $27.50, and currently trades 35.6% below its 52-week high.

On profitability, Daiichi Sankyo Company, Limited generates a return on equity (ROE) of 14.44%, above the typical market average, return on capital employed of 5.86%, an operating margin of 8.83%, a net profit margin of 10.93%.

In its most recent fiscal year, Daiichi Sankyo Company, Limited reported annual revenue of $2.25T, net profit of $275.5B, revenue has compounded at 18.5% a year over the last five years, profit at 29.4% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.29 — a conservative balance sheet with little leverage risk, a current ratio of 2.92, total assets of $4.02T, $451.8B in cash and equivalents.

DSNKY has an average daily trading volume of 281,644 shares, a beta of 0.14 (less volatile than the overall market).

Official website: www.daiichisankyo.com